orphan date December 2009 The Anti apoptotic Ras signalling cascade is an intracellular signal transduction cascade that involves the Ras protein Ras protein and inhibits apoptosis . It is the target of the cancer drug gefitinib . It may refer to the PI3K AKT pathway ref http www.ncbi.nlm.nih.gov pubmed 15284455 Gefitinib sensitizing EGFR mutations in lung cancer activate anti apoptotic pathways. 2004 ref ref http genesdev.cshlp.org content 11 6 701.abstract The PI 3 kinase Akt signaling pathway delivers an anti apoptotic signal 1997 ref ref http www.springerlink.com content 86l52127046nx383 2Hypoinsulinemia Alleviates the Grf1 Ras Akt Anti Apoptotic Pathway and Induces Alterations of Mitochondrial Ras Trafficking in Neuronal Cells 2009 ref . It may refer to the MAPK ERK pathway which involves ras and can affect apoptosis. ref http cancerres.aacrjournals.org cgi content abstract 67 21 10343 Suppression of PTEN Expression Is Essential for Antiapoptosis and Cellular Transformation by Oncogenic Ras 2007 ref ref http www.aacrmeetingabstracts.org cgi content abstract 2005 1 972 b Pathways potentiated by oncogenic Ras to modulate apoptosis induced by anticancer agent FR901228 2005 ref The anti apoptotic STAT protein STAT pathway does not involve Ras. See also Empty section date June 2010 References reflist External links http www.biocarta.com pathfiles h raspathway.asp Diagram of ras onwards. DEFAULTSORT Anti Apoptotic Ras Signalling Cascade Category Signal transduction Category Cell cycle Category Apoptosis biology stub ... more details
options include gefitinib epidermal growth factor receptor tyrosine kinase inhibitor ref name pmid16009452 cite journal author Kitazaki T, Soda H, Doi S, Nakano H, Nakamura Y, Kohno S title Gefitinib ... name pmid15949598 cite journal author Kitazaki T, Fukuda M, Soda H, Kohno S title Novel effects of gefitinib ... in patients with bronchioloalveolar carcinoma treated with gefitinib Iressa journal Support ... bronchorrhea by gefitinib in a case with Recurrent Bronchioloalveolar Carcinoma a case report journal ... more details
This is a list of specific Wiktionary pharmacological agent pharmacologic agents that are known to be of use in the treatment of cancer , otherwise known as Wiktionary chemotherapeutic agent chemotherapeutic agents . This list is organized by type of agent, though the subsections are not necessarily definitive and are subject to revision. Each drug is listed once at present , though it might fall in more than one subsection. A full alphabetical listing is included after the categorical listing. Expand list date August 2008 Alkylating agents Cyclophosphamide Mechlorethamine Chlorambucil Melphalan Anthracyclines article on anthracycline s Daunorubicin Doxorubicin Epirubicin Idarubicin Mitoxantrone Valrubicin Cytoskeletal disruptors Taxanes Paclitaxel Docetaxel Epothilones article on epothilone s Histone Deacetylase Inhibitors Vorinostat Romidepsin Inhibitors of Topoisomerase II Etoposide Teniposide Tafluposide Kinase Inhibitors Bortezomib Erlotinib Gefitinib Imatinib Vismodegib Monoclonal Antibodies Bevacizumab Cetuximab Ipilimumab Ofatumumab Ocrelizumab Panitumab Rituximab Vemurafenib Nucleotide analogs and precursor analogs Azacitidine Azathioprine Capecitabine Cytarabine Doxifluridine Fluorouracil Gemcitabine Hydroxyurea Mercaptopurine Methotrexate Tioguanine formerly Thioguanine Peptide antibiotics Bleomycin Actinomycin Platinum based agents Carboplatin Cisplatin Oxaliplatin Retinoids Tretinoin Alitretinoin Bexarotene Vinca alkaloids and derivatives Vinblastine Vincristine Vindesine Vinorelbine Full alphabetical listing Actinomycin All trans retinoic acid Azacitidine Azathioprine Bleomycin Bortezomib Carboplatin Capecitabine Cisplatin Chlorambucil Cyclophosphamide Cytarabine Daunorubicin Docetaxel Doxifluridine Doxorubicin Epirubicin Epothilone Etoposide Fluorouracil Gemcitabine Hydroxyurea Idarubicin Imatinib Mechlorethamine Mercaptopurine Methotrexate Mitoxantrone Oxaliplatin Paclitaxel Pemetrexed Teniposide Tioguanine Valrubicin Vinblastine Vincristine Vindesin ... more details
can also be treated with Erlotinib or Gefitinib ref http feelsynapsis.com pg file read 65613 treatment of nonsmallcell lung cancer with erlotinib or gefitinib ref References Reflist External links ... more details
2992 Monotherapy in Non small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib ref Fall 2010 ... by first generation TKIs like erlotinib or gefitinib , but also against those not sensitive ... more details
Refimprove date November 2008 Infobox Company company name Nanjing Ange Pharmaceutical Co. br company logo foundation 2003 company slogan Quality Technology and Service Foster Healthy Life location Nanjing, Jiangsu Province , People s Republic of China industry Pharmaceuticals , br Healthcare products Antineoplastic medicine , br pharmaceutical intermediates num employees 35 2007 num associates 8 homepage http www.angepharm.com template gsjja en.htm www.angepharm.com Nanjing Ange Pharmaceutical Co., Ltd. zh s t p N nj ng ng y y o hu g ng y uxi n g ngs is a pharmaceutical company in Nanjing , in the People s Republic of China , specializing in the development of New Drug s the drugs that previously have not been marketed in China, i.e., New Chemical Entities for China s FDA as well as the research, development, production and trade of chemical API s and pharmaceutical Intermediate goods intermediate s. Company Profile Ange was founded in 2003, and is now a leading company in the Chinese pharmaceutical industry . With almost every major university in Nanjing Ange has established cooperative relationships and laboratories, including China Pharmaceutical University , China s first independent school of pharmacy and one of the few institutes with complete pharmaceutical fields ref China Pharmaceutical University ref . Main Products Ange s main products are Antineoplastic medicines, which include Sunitinib Lapatinib Nilotinib Dasatinib Gefitinib Erlotinib Imatinib Canertinib It also produces relative pharmaceutical intermediates. Recent Projects In the past 2 years, Ange has been working with Abbott Laboratories Ltd. and Simcere Pharmaceutical Group , etc. ref cite web url http www.angepharm.com template gsjja en.htm title About Us ref References reflist External links http www.angepharm.com template gsjja en.htm Ange Official Web Site en Pharmaceutical companies of China Category Biotechnology companies Category Pharmaceutical co ... more details
Orphan date July 2011 Nicholas Thatcher is Professor of Oncology at the University of Manchester , in the School of Cancer and Imaging Sciences at the Christie Hospital NHS Trust and Wythenshawe Hospital he was appointed to the position of Professor in 1996. ref http www.timesonline.co.uk tol life and style health article6624061.ece Times Online, Jul 2, 2009 ref He received his PhD from Manchester University , after prior education at the University of Cambridge and St Bartholomew s Hospital Medical College St Bartholomew s Hospital Medical College, London His specialty is clinical and translational research in renal cell cancer, melanoma and lung cancer . He was investigator in key clinical trials dealing with chemotherapy methods and dosages in small cell lung cancer and small cell lung cancer. He has written of several hundred peer reviewed papers in major scientific medical journals ref Journal of Clinical Oncology, Vol 24, No 31 November 1 , 2006 pp. 5034 5042 http jco.ascopubs.org content 24 31 5034.full cited 429 times according to Google Scholar ref and has directed several PhD thesis. He is joint editor of the textbook , New perspectives in lung cancer edited by Nick Thatcher and Stephen Spiro. , 2nd ed, Edited by Martin Muers, Nicholas Thatcher, Francis Wells & Andrew Miles. London BMJ Publishing, 1994. ISBN 0727907867. ref http catalogue.bl.uk 80 F H8MYKECA3Q5D8866DUF6T4JXF7VIXI6M8SIS7KY9H4L5CV3YNH 00183?func full set set&set number 015533&set entry 000002&format 999 British Library Catalog ref His most cited papers, according to Google Scholar ref http scholar.google.com scholar?q Nicholas Thatcher Oncology&hl en&btnG Search&as sdt 20000000001&as sdtp on ref are Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo Controlled Study in Advanced Non Small Cell Lung Cancer, by Fred R. Hirsch, Marileila Varella Garcia, Paul A. Bunn, Jr, Wilbur A. Franklin, Rafal Dziadziuszko, Nick Thatcher, Alex Chang, Purvish Parikh, Jos Rodrigues Pereira, ... more details
at a cost of CDN 95,000. Mechanism Erlotinib is an EGFR inhibitor . The drug follows Iressa gefitinib ... histology correlates with clinical benefit in patients treated with gefitinib as a therapy ... F, Mok T, Lee C, Johnson BE, Cantley LC, J nne PA title MET Amplification Leads to Gefitinib ... lung tumors with acquired resistance to gefitinib or erlotinib. journal PNAS volume 104 issue 52 pages ... signalling and acquired resistance to gefitinib ZD1839 Iressa in human breast and prostate cancer ... journal pmid 15284455 doi 10.1126 science.1101637 volume 305 issue 5687 title Gefitinib sensitizing ... more details
factor 1 receptor Burstein et al. 2008 Gefitinib and Erlotinib inhibit the tyrosine kinase domain ... JJ, Kay AC title Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine ... kinase was assessed in a clinical trial. ref name Kris 2003 In this case, Gefitinib is the inhibitor .... ref name Sordella 2004 cite journal author Sordella R, Bell DW, Haber DA, Settleman J title Gefitinib ... issn ref Gefitinib is a tyrosine kinase inhibitor that targets the epidermal growth factor receptor ... kinase inhibitors as potential targets in cancer treatment. Gefitinib, functioning as an epidermal growth ... cell lung cancer cells become dependent on these survival signals. Gefitinib s inhibition of the survival .... ref name Sordella 2004 Gefitinib is well endured by humans, and treatment resulted in a symptom ... mg of Gefitinib and 35 with 95 confidence in a 26 45 interval for those that received 500 mg .... ref name Kris 2003 Gefitinib application once per day caused rapid symptom improvement and tumor regressions ... to the discoveries made in this trial. The side effects of Gefitinib oral treatment once per day were ... mg group. Nevertheless the side effects of Gefitinib were only generally mild, manageable ... be the only reversal strategy of the unfavorable symptoms. ref name Kris 2003 Gefitinib still represents ... more details
preceding role at AstraZeneca led to the development of one of the first targeted medicines gefitinib ... theoncologist.alphamedpress.org content 8 4 303.full title FDA Drug Approval Summary Gefitinib ZD1839 ... more details
may be effective in treatment of dermatofibrosarcoma protuberans . Gefitinib Iressa, also known ... http www.jhoonline.org content 2 1 2 pmc 2637898 ref and works through a similar mechanism as gefitinib ... as second line therapy. Because of this finding, erlotinib has replaced gefitinib in this setting ... more details
ErbB 1 is overexpressed in many cancers. Drugs such as panitumumab , cetuximab , gefitinib , erlotinib are used to inhibit it. It has recently been shown that acquired resistance to cetuximab and gefitinib ... J.A., Zejnullahu K. et al title MET amplification leads to gefitinib resistance in lung cancer by activating ... more details
Orphan date February 2009 PBB geneid 2012 Epithelial membrane protein 1 is a protein that in humans is encoded by the EMP1 gene . ref name pmid8996089 cite journal author Ben Porath I, Benvenisty N title Characterization of a tumor associated gene, a member of a novel family of genes encoding membrane glycoproteins journal Gene volume 183 issue 1 2 pages 69 75 year 1997 month Feb pmid 8996089 pmc doi 10.1016 S0378 1119 96 00475 1 ref ref name pmid9126480 cite journal author Chen Y, Medvedev A, Ruzanov P, Marvin KW, Jetten AM title cDNA cloning, genomic structure, and chromosome mapping of the human epithelial membrane protein CL 20 gene EMP1 , a member of the PMP22 family journal Genomics volume 41 issue 1 pages 40 8 year 1997 month May pmid 9126480 pmc doi 10.1006 geno.1997.4524 ref ref name entrez cite web title Entrez Gene EMP1 epithelial membrane protein 1 url http www.ncbi.nlm.nih.gov sites entrez?Db gene&Cmd ShowDetailView&TermToSearch 2012 accessdate ref The PBB Summary template is automatically maintained by Protein Box Bot. See Template PBB Controls to Stop updates. PBB Summary section title summary text References reflist Further reading refbegin 2 PBB Further reading citations cite journal author Jain A, Tindell CA, Laux I, et al. title Epithelial membrane protein 1 is a biomarker of gefitinib resistance journal Proc. Natl. Acad. Sci. U.S.A. volume 102 issue 33 pages 11858 63 year 2005 pmid 16087880 doi 10.1073 pnas.0502113102 pmc 1187965 cite journal author Gerhard DS, Wagner L, Feingold EA, et al. title The Status, Quality, and Expansion of the NIH Full Length cDNA Project The Mammalian Gene Collection MGC journal Genome Res. volume 14 issue 10B pages 2121 7 year 2004 pmid 15489334 doi 10.1101 gr.2596504 pmc 528928 cite journal author Wang HT, Kong JP, Ding F, et al. title Analysis of gene expression profile induced by EMP 1 in esophageal cancer cells using cDNA Microarray journal World J. Gastroenterol. volume 9 issue 3 pages 392 8 year 2003 pmid 12632 ... more details
been developed for the treatment of advanced lung cancer. Gefitinib Iressa is one such drug, which ... gefitinib. ref name Raz Cite journal last Raz first DJ coauthors He B, Rosell R, Jablons DM title ... gefitinib and erlotinib in the treatment of non small cell lung cancer a systematic review journal ... 0790 url http clincancerres.aacrjournals.org content 11 18 6414.long ref Similar to gefitinib, it also ... more details
www.tarceva.com ref Gefitinib Iressa ref name Iressa http www.iressa.com ref Monoclonal Antibody against ... K, Fukuoka M title EGFR mutation in gefitinib responsive small cell lung cancer journal Annals ... growth factor receptor kinase inhibitors erlotinib and gefitinib journal Archives of Pathology ... more details
growth factor receptor underlying responsiveness of non small cell lung cancer to gefitinib ... against EGFR, including gefitinib ref name pmid15118125 cite journal author Paez JG, J nne PA, Lee ... with clinical response to gefitinib therapy journal Science volume 304 issue 5676 pages 1497 500 year ... for growth, tumor proliferation and migration is diminished. Gefitinib , erlotinib , and lapatinib ... more details
Encyclopedia
top
